Clinical Trials Logo

Type 2 Diabetes (T2DM) clinical trials

View clinical trials related to Type 2 Diabetes (T2DM).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03459079 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease (NAFLD)

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Start date: August 14, 2018
Phase: Phase 2
Study type: Interventional

The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Specifically, to determine if lanifibranor decreases intrahepatic triglycerides (IHTG) (primary endpoint), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles. In addition, exploratory analysis with surrogate plasma biomarkers and imaging on liver fibrosis changes on with treatment will be performed.